References
- Bayer-Garner IB, Smoller BR. The spectrum of cutaneous disease in multiple myeloma. J Am Acad Dermatol 2003; 48: 497–507
- Gado K., Silva S, Pálóczi K, et al. Mouse plasmocytoma: An experimental model of human multiple myeloma. Haematologica 2001; 86: 227–36
- Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, et al. Insight into extramedullary tumour cell growth revealed by expression profiling of human plasmocytomas and multiple myeloma. Brit J Haematol 2003; 122: 728–44
- Várkonyi J, Zalatnai A, Tímár J, et al. Secondary cutaneous infiltration in B cell chronic lymphocytic leukemia. Acta Haematol 2000; 103: 116–21
- Kahlson G. A place for histamine in normal physiology. Lancet 1960; I: 67–71
- Bartholeyns J, Bouclier M. Involvement of histamine in growth of mouse and rat tumors: Antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase. Carcer Res 1984; 44: 639–45
- Quintana FJ, Buzas E, Prohászka Z, Bíró A, Kocsis J, Füst G, et al. Knock-out of the histidine decarboxylase gene modofies the repertoire of natural autoantibodies. J Autoimmun 2004; 22: 297–305
- Tarkovács G, Ujvary B, Panczel P, Berczi L, Palinger E, Matolcsy A, et al. Losing histidine decarboxylase immunreactivity appears to be a regularity in the development of secondary cutaneous B-cell lymphoma. EORTC Cutaneous Lymphoma Task Force Clinical Meeting Budapest, 22–24 September 2006.
- Bencsáth M, Pálóczi K, Szalai CS, Szenthe A, Szeberényi J, Falus A. Histidine decarboxylase in peripheral lymphocytes of healthy individuals and chronic lymphoid leukemia patients. Pathol Oncol Res 1998; 4: 121–4
- Brandes LJ, LaBella FS, Warrington RC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 1991; 83: 1329–36
- Naredi P. Histamine as adjunct to immunotherapy. Semin Oncol 2002; 29: 31–4
- Ahlberg R, MacNamara B, Andersson M, et al. Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-α and histamine treatment. Hematol J 2003; 4: 295–302
- Cornelissen JJ, Ploemacher RE, Wognum BW, Borsboom A, Kluin-Nelemans HC, Hagemeijer A, et al. An in vitro model for cytogenetic conversion in CML. IFNα preferentially inhibits the outgrowth of malignant stem cells preserved in long term culture. J Clin Invest 1998; 102: 976–83
- Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood 2000; 95: 1900–10